Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DMN002
MIFTS: 68

Dementia

Categories: Mental diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Dementia

About this section

MalaCards integrated aliases for Dementia:

Name: Dementia 12 76 54 29 55 6 43 3 15 40 73
Presenile Dementia 73

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1307
ICD9CM 35 290.8
Sources

Summaries for Dementia

About this section
NINDS : 54 Dementia is the loss of cognitive functioning—the ability to think, remember, problem solve or reason—to such an extent that it interferes with a person’s daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person’s functioning, to the most severe stage, when the person must depend completely on others for basic activities of daily living. Functions affected include memory, language skills, visual perception, problem solving, self-management, and the ability to focus and pay attention. Some people with dementia cannot control their emotions, and their personalities may change. Signs and symptoms of dementia result when once-healthy neurons (nerve cells) in the brain stop working, lose connections with other brain cells, and die. While everyone loses some neurons as they age, people with dementia experience far greater loss. Unlike dementia, age-related memory loss isn’t disabling. While dementia is more common with advanced age (as many as half of all people age 85 or older may have some form of dementia), it is not normal part of aging. Many people live into their 90s and beyond without any signs of dementia. The causes of dementia can vary. Many people with dementia have both Alzheimer’s disease and one or more closely related disorders that share brain scanning or clinical (and sometimes both) features with Alzheimer’s disease. When a person is affected by more than one dementia disorder, the dementia can be referred to as a mixed dementia. Some people may have mixed dementia caused by Alzheimer’s-related neurodegenerative processes, vascular disease-related processes, or another neurodegenerative condition. Many other conditions such as Creutzfeldt-Jakob disease, Huntington’s Disease, and chronic traumatic encephalopathy can cause dementia or dementia-like symptoms. Risk factors for dementia include advancing age, stroke, high blood pressure, poorly controlled diabetes, and a thickening of blood vessel walls (atherosclerosis). Other dementias include frontotemporal disorders, vascular dementia, and Lewy body dementia.

MalaCards based summary : Dementia, also known as presenile dementia, is related to vascular dementia and semantic dementia, and has symptoms including angina pectoris, back pain and headache. An important gene associated with Dementia is MAPT (Microtubule Associated Protein Tau), and among its related pathways/superpathways are Neuroscience and Presenilin-Mediated Signaling. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and cellular

MedlinePlus : 43 Dementia is the name for a group of symptoms caused by disorders that affect the brain. It is not a specific disease. People with dementia may not be able to think well enough to do normal activities, such as getting dressed or eating. They may lose their ability to solve problems or control their emotions. Their personalities may change. They may become agitated or see things that are not there. Memory loss is a common symptom of dementia. However, memory loss by itself does not mean you have dementia. People with dementia have serious problems with two or more brain functions, such as memory and language. Although dementia is common in very elderly people, it is not part of normal aging. Many different diseases can cause dementia, including Alzheimer's disease and stroke. Drugs are available to treat some of these diseases. While these drugs cannot cure dementia or repair brain damage, they may improve symptoms or slow down the disease. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 The role of public health in enhancing the physical health of older adults is well-known. Public health’s role in maintaining cognitive health, a vital part of healthy aging and quality of life, is emerging. The need for a clearly delineated public health role comes at a critical time given the dramatic aging of the U.S. population, scientific advancements in knowledge about risk behaviors (e.g., lack of physical activity, uncontrolled high blood pressure) related to cognitive decline, and the growing awareness of the significant health, social, and economic burdens associated with cognitive decline. The Healthy Brain Initiative is a multifaceted approach to cognitive health with several components, including:

Disease Ontology : 12 A cognitive disorder resulting from a loss of brain function affecting memory, thinking, language, judgement and behavior.

Wikipedia : 76 Dementia is a broad category of brain diseases that cause a long-term and often gradual decrease in the... more...

Sources

Related Diseases for Dementia

About this section

Diseases related to Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 604)
# Related Disease Score Top Affiliating Genes
1 vascular dementia 34.9 APOE APP MAPT NOTCH3 PSEN1
2 semantic dementia 34.7 APOE C9orf72 CHMP2B GRN MAPT PSEN1
3 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 34.6 C9orf72 CHCHD10 CHMP2B GRN PSEN1 SQSTM1
4 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 34.6 GRN MAPT
5 inclusion body myopathy with paget disease of bone and frontotemporal dementia 34.6 TARDBP VCP
6 dementia, lewy body 34.1 APOE APP GBA GRN MAPT PRNP
7 behavioral variant of frontotemporal dementia 34.0 C9orf72 CHMP2B GRN MAPT PSEN1 SQSTM1
8 binswanger's disease 34.0 APOE APP MAPT NOTCH3
9 cerebral amyloid angiopathy, itm2b-related, 1 34.0 APP ITM2B
10 pick disease of brain 33.9 APOE APP GRN MAPT PSEN1 SNCA
11 prion disease 33.7 APP MAPT PRNP
12 frontotemporal dementia 33.7 APOE APP C9orf72 CHCHD10 CHMP2B GRN
13 leukoencephalopathy, hereditary diffuse, with spheroids 33.7 APP MAPT PRNP SNCA
14 creutzfeldt-jakob disease 33.7 APOE MAPT PRNP
15 alzheimer disease 33.4 APOE APP GRN ITM2B MAPT PRNP
16 posterior cortical atrophy 33.1 APOE MAPT
17 corticobasal degeneration 33.0 GBA MAPT TARDBP
18 genetic prion diseases 33.0 APOE PRNP
19 multiple system atrophy 1 33.0 MAPT SNCA SNCB SQSTM1
20 amyotrophic lateral sclerosis 1 32.9 APP C9orf72 CHCHD10 CHMP2B GRN MAPT
21 cerebral amyloid angiopathy, cst3-related 32.9 APOE APP ITM2B MAPT PRNP PSEN1
22 niemann-pick disease, type c1 32.9 APP MAPT SNCA
23 supranuclear palsy, progressive, 1 32.8 APOE APP C9orf72 GRN MAPT PSEN1
24 progressive non-fluent aphasia 32.7 C9orf72 CHMP2B GRN MAPT PSEN1 VCP
25 amyotrophic lateral sclerosis 21 32.7 C9orf72 TARDBP VCP
26 alzheimer disease 2 32.7 APOE APP MAPT PSEN1 PSEN2
27 perry syndrome 32.6 C9orf72 GRN SNCA TARDBP
28 parkinson disease, late-onset 32.6 APOE APP GBA MAPT SNCA SNCB
29 aphasia 32.5 APOE APP C9orf72 CHMP2B GRN MAPT
30 synucleinopathy 32.5 APP CHMP2B GBA MAPT SNCA SNCB
31 kluver-bucy syndrome 32.4 APP MAPT PSEN1
32 alzheimer disease 4 32.4 APOE PSEN1 PSEN2
33 familial idiopathic basal ganglia calcification 32.1 APOE APP MAPT PSEN1 PSEN2
34 lateral sclerosis 32.0 C9orf72 CHCHD10 SQSTM1 TARDBP TRPM7 VCP
35 apraxia 31.6 C9orf72 GRN MAPT PSEN1
36 motor neuron disease 31.6 C9orf72 CHCHD10 GRN MAPT SNCA SQSTM1
37 tremor 31.5 GBA MAPT SNCA
38 alexia 31.4 APOE PSEN1 TARDBP
39 amyloidosis 31.2 APOE APP PSEN1 SNCA
40 prosopagnosia 31.1 GRN PSEN1
41 gait apraxia 30.9 APOE APP GRN PSEN1
42 agraphia 30.9 GRN MAPT PRNP PSEN1 TARDBP
43 early-onset, autosomal dominant alzheimer disease 30.9 APP PSEN1 PSEN2
44 dysautonomia 30.8 GBA PRNP SNCA
45 simultanagnosia 30.8 APOE MAPT
46 senile plaque formation 30.8 APOE APP
47 movement disease 30.7 GBA MAPT SNCA
48 ideomotor apraxia 30.7 GRN MAPT PSEN1 TARDBP
49 speech and communication disorders 30.7 APOE C9orf72 GRN MAPT PSEN1 TARDBP
50 visual agnosia 30.6 GRN PSEN1 PSEN2

Graphical network of the top 20 diseases related to Dementia:



Diseases related to Dementia
Sources

Symptoms & Phenotypes for Dementia

About this section

UMLS symptoms related to Dementia:


angina pectoris, back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, equilibration disorder, sleeplessness

MGI Mouse Phenotypes related to Dementia:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 NOTCH3 PSEN1 ITM2B MAPT PRNP SNCA
2 cellular MP:0005384 10.47 NOTCH3 PSEN1 MAPT PRNP SNCA TARDBP
3 growth/size/body region MP:0005378 10.41 NOTCH3 PSEN1 MAPT PRNP SNCA SNCB
4 hematopoietic system MP:0005397 10.37 NOTCH3 PSEN1 GRN MAPT PRNP PSEN2
5 immune system MP:0005387 10.36 NOTCH3 PSEN1 MAPT PRNP SNCA PSEN2
6 homeostasis/metabolism MP:0005376 10.35 NOTCH3 GRN MAPT PRNP SQSTM1 SNCA
7 mortality/aging MP:0010768 10.31 NOTCH3 GRN MAPT PRNP SNCA PSEN1
8 nervous system MP:0003631 10.3 NOTCH3 PSEN1 ITM2B MAPT PRNP SNCA
9 cardiovascular system MP:0005385 10.25 NOTCH3 MAPT SNCA PSEN1 PSEN2 VCP
10 endocrine/exocrine gland MP:0005379 10.18 PRNP NOTCH3 SNCA PSEN1 PSEN2 TYROBP
11 integument MP:0010771 10.17 NOTCH3 MAPT PRNP SQSTM1 SNCA PSEN1
12 muscle MP:0005369 9.97 NOTCH3 MAPT PRNP PSEN1 TARDBP VCP
13 no phenotypic analysis MP:0003012 9.96 GRN ITM2B MAPT PRNP SNCA SNCB
14 normal MP:0002873 9.85 NOTCH3 MAPT PRNP SNCA PSEN1 SNCB
15 renal/urinary system MP:0005367 9.5 NOTCH3 MAPT SNCA PSEN1 PSEN2 TRPM7
16 skeleton MP:0005390 9.36 NOTCH3 PRNP SQSTM1 SNCA PSEN1 SNCB
Sources

Drugs & Therapeutics for Dementia

About this section

Drugs for Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 883)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 19982-08-2 4054
3
Levodopa Approved Phase 4,Phase 2,Phase 3,Phase 1 59-92-7 6047
4
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59729-33-8 2771
5
Galantamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 357-70-0 9651
6
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 106266-06-2 5073
7
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120014-06-4 3152
8
Huperzine A Approved, Investigational Phase 4,Phase 2,Phase 3 102518-79-6
9
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
10
Nitrous oxide Approved, Vet_approved Phase 4,Not Applicable 10024-97-2 948
11
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
12
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123441-03-2 77991
13
Ketamine Approved, Vet_approved Phase 4,Phase 3 6740-88-1 3821
14
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
15 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 979-32-8
16
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 71-58-9
17
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
18
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3 57-83-0 5994
19
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
20
Nimodipine Approved, Investigational Phase 4,Phase 2,Phase 1 66085-59-4 4497
21
Rasagiline Approved Phase 4,Phase 2 136236-51-6 3052776
22
Aspirin Approved, Vet_approved Phase 4,Not Applicable 50-78-2 2244
23
Cilostazol Approved, Investigational Phase 4,Phase 2,Not Applicable 73963-72-1 2754
24
Probucol Approved, Investigational Phase 4,Phase 1,Phase 2 23288-49-5 4912
25
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 93-14-1 3516
26
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Not Applicable 13422-51-0 11953898 44475014
27
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 112111-43-0
28
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68693-11-8 4236
29
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 113-45-1 4158
30
Dextromethorphan Approved Phase 4,Phase 3,Phase 1,Phase 2 125-71-3 5360696 5362449
31
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Early Phase 1 15687-27-1 3672
32
Nicotine Approved Phase 4,Phase 2,Phase 1,Not Applicable 54-11-5 942 89594
33
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 2078-54-8 4943
34
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
35
Isoflurane Approved, Vet_approved Phase 4,Phase 1,Not Applicable 26675-46-7 3763
36
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 99-66-1 3121
37
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
38
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
39
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
40
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 61869-08-7 43815
41
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 79617-96-2 68617
42
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 52485-79-7 40400 644073
43
Methamphetamine Approved, Illicit Phase 4,Not Applicable 537-46-2 10836
44
Olanzapine Approved, Investigational Phase 4,Phase 3,Not Applicable 132539-06-1 4585
45
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
46 Piracetam Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7491-74-9
47
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
48
Quinidine Approved, Investigational Phase 4,Phase 3,Phase 2 56-54-2 441074
49
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
50
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 1 129722-12-9 60795

Interventional clinical trials:

(show top 50) (show all 3191)
# Name Status NCT ID Phase Drugs
1 Memantine for Agitation in Dementia Unknown status NCT00371059 Phase 4 Memantine;Placebo
2 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment Unknown status NCT00306124 Phase 4 Levodopa
3 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
4 The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD) Unknown status NCT00626613 Phase 4 Risperdal,reminyl
5 Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI Unknown status NCT01329601 Phase 4
6 CALM-AD Unknown status NCT00142324 Phase 4 Donepezil
7 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
8 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
9 Donepezil and Memantine in Moderate to Severe Alzheimer's Disease Unknown status NCT00866060 Phase 4 Memantine;Donepezil;Placebo donepezil;Placebo memantine
10 International Substudy Enigma2 on Postoperative Cognitive Disorders Unknown status NCT02489097 Phase 4 Nitrous Oxide
11 Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study Unknown status NCT02409238 Phase 4 Metformin
12 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4 Rivastigmine
13 Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study Unknown status NCT02190019 Phase 4
14 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
15 Cognitive Decline in Non-demented PD Unknown status NCT01340885 Phase 4 Strattera;Exelon
16 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
17 The Role of Ketamine in Preventing Cognitive Dysfunctions in Postoperative Period of Cardiac Surgery Unknown status NCT02782429 Phase 4 Ketamine
18 Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®) Unknown status NCT00523666 Phase 4 Galantamine (Reminyl®);Placebo/Galantamine (Reminyl®)
19 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
20 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
21 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4 AZILECT®;Placebo
22 Study of Memantine to Treat Huntington's Disease Unknown status NCT00652457 Phase 4 Memantine
23 PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
24 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed NCT00385684 Phase 4 hydrocodone/APAP w placebo PRN;hydrocodone/APAP;placebo with hydrocodone/APAP PRN
25 Cilostazol Augmentation Study in Dementia Completed NCT01409564 Phase 4 Cilostazol;Placebo
26 Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
27 Corticolimbic Degeneration and Treatment of Dementia Completed NCT00768261 Phase 4 Memantine (Namenda®);Memantine (Namenda®);Donepezil (Aricept®)
28 Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia Completed NCT01585272 Phase 4 ENA713
29 Dementia Antipsychotics And Antidepressants Discontinuation Study Completed NCT00594269 Phase 4 Risperidone;Escitalopram;Citalopram;Sertraline;Paroxetine
30 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
31 Can Oral Vitamin B12 and Folate Supplementation Preserve Cognitive Function of Patients With Early Dementia? Completed NCT00164970 Phase 4
32 Effect of Melatonin on Sleep Quality in Patients Dementia Completed NCT03066518 Phase 4 Melatonin 5 mg
33 The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life Completed NCT00814658 Phase 4 Galantamine;Nimodipine;Placebo
34 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
35 Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4 Memantine;Placebo
36 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4 Armodafinil
37 Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and Mini Mental State Examination (MMSE)Range 5 - 18 Completed NCT02553928 Phase 4 Memantine (once daily);Memantine (twice daily)
38 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
39 Study on the Efficacy of Speed-Feedback Therapy for Elderly People With Dementia Completed NCT00450047 Phase 4
40 Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study Completed NCT00495820 Phase 4 Methylphenidate
41 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions Completed NCT00847860 Phase 4 Cilostazol;Aspirin
42 Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD Completed NCT00433121 Phase 4 Risperidone;Olanzapine;Haloperidole;Quetiapin;Escitalopram;Citalopram;Sertralin
43 A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
44 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4 Quetiapine
45 A Comparison of Two Standard Therapies in the Management of Dementia With Agitation Completed NCT00208819 Phase 4 risperidone;quetiapine;olanzapine;divalproex
46 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 Completed NCT00948766 Phase 4 Rivastigmine 4.6 mg/24 h (5 cm^2);Rivastigmine 9.5 mg/24 h (10 cm^2);Rivastigmine 13.3 mg/24 h (15 cm^2);Placebo
47 A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints Completed NCT00276510 Phase 4 EGb 761® (Tanakan®)
48 The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia. Completed NCT00165711 Phase 4 Mecobalamin
49 Donepezil to Treat Dementia in Parkinson's Disease Completed NCT00030979 Phase 4 Donepezil
50 Rivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia. Completed NCT02413554 Phase 4 Rivastigmine patch

Search NIH Clinical Center for Dementia

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Dementia

About this section

Genetic tests related to Dementia:

# Genetic test Affiliating Genes
1 Dementia 29
Sources

Anatomical Context for Dementia

About this section

MalaCards organs/tissues related to Dementia:

41
Brain, Testes, Heart, Cortex, Bone, Eye, Temporal Lobe
Sources

Publications for Dementia

About this section

Articles related to Dementia:

(show top 50) (show all 5790)
# Title Authors Year
1
Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer's disease. ( 29441654 )
2018
2
Enhanced Positive Emotional Reactivity Undermines Empathy in Behavioral Variant Frontotemporal Dementia. ( 29915557 )
2018
3
Executive and social-cognitive determinants of environmental dependency syndrome in behavioral frontotemporal dementia. ( 29809029 )
2018
4
Anosognosia predicts default mode network hypometabolism and clinical progression to dementia. ( 29444971 )
2018
5
A new device-aided cognitive function test, User eXperience-Trail Making Test (UX-TMT), sensitively detects neuropsychological performance in patients with dementia and Parkinson's disease. ( 29976167 )
2018
6
Meaning of psychiatric symptoms in frontotemporal dementia. ( 29439161 )
2018
7
Dementia management: a brief overview for primary care clinicians. ( 29974121 )
2018
8
Strategic value-directed learning and memory in Alzheimer's disease and behavioural-variant frontotemporal dementia. ( 29431279 )
2018
9
Visual texture agnosia in dementia with Lewy bodies and Alzheimer's disease. ( 29673784 )
2018
10
Molecular Genetics of Frontotemporal Dementia Elucidated by <i>Drosophila</i> Models-Defects in Endosomala8>Lysosomal Pathway. ( 29890743 )
2018
11
Vascular dementia: clinicopathologic and genetic considerations. ( 29380913 )
2018
12
Predicting outcome of Morris water maze test in vascular dementia mouse model with deep learning. ( 29415035 )
2018
13
Correction: Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. ( 29377952 )
2018
14
Posterior Associative and Cingulate Cortex Involvement of Brain Single-Photon Emission Computed Tomography (SPECT) Imaging in Semantic Dementia with Probable Alzheimer Disease Pathology: A Case Report. ( 29429985 )
2018
15
Chinese Herbal Medicine for Vascular Dementia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. ( 29439346 )
2018
16
Genomea89wide DNA methylation profiling in a rat model with vascular dementia. ( 29749552 )
2018
17
Differential diagnosis of unexplained falls in dementia: Results of &amp;quot;Syncope &amp;amp; Dementia&amp;quot; registry. ( 29398249 )
2018
18
Diagnosing pre-clinical dementia: the NZ Genetic Frontotemporal Dementia Study (FTDGeNZ). ( 29879731 )
2018
19
Trichotillomania Ranging from &amp;quot;Ritual to Illness&amp;quot; and as a Rare Clinical Manifestation of Frontotemporal Dementia: Review of Literature and Case Report. ( 29769783 )
2018
20
Betulinic acid, a natural PDE inhibitor restores hippocampal cAMP/cGMP and BDNF, improve cerebral blood flow and recover memory deficits in permanent BCCAO induced vascular dementia in rats. ( 29778746 )
2018
21
Neurovascular dysfunction in dementia - human cellular models and molecular mechanisms. ( 29444850 )
2018
22
Plasma amyloid-I^ levels, cerebral atrophy and risk of dementia: a population-based study. ( 29960604 )
2018
23
Affective Empathy in Behavioral Variant Frontotemporal Dementia: A Meta-Analysis. ( 29946291 )
2018
24
Stroke Risk and Vascular Dementia in South Asians. ( 29974259 )
2018
25
EEG Differences in Two Clinically Similar Rapid Dementias: Voltage-Gated Potassium Channel Complex-Associated Autoimmune Encephalitis and Creutzfeldt-Jakob Disease. ( 29788790 )
2018
26
Frontotemporal dementia with Parkinsonism linked to chromosome-17 mutations enhance tau oligomer formation. ( 29852407 )
2018
27
Potential of carnosine, a histamine precursor in rat model of bilateral common carotid artery occlusion-induced vascular dementia. ( 29676814 )
2018
28
Special Issue on mild behavioral impairment and non-cognitive prodromes to dementia. ( 29448971 )
2018
29
Cathepsin D Polymorphism C224T in Childhood-Onset Neurodegenerative Disorders: No Impact for Childhood Dementia. ( 29441216 )
2018
30
Polypharmacy in people with dementia: Associations with adverse health outcomes. ( 29452289 )
2018
31
Relationships Between Cognitive Complaints and Quality of Life in Older Adults With Mild Cognitive Impairment, Mild Alzheimer Disease Dementia, and Normal Cognition. ( 29944474 )
2018
32
Sleep Apnea Is a Risk Factor for Stroke and Vascular Dementia. ( 29938308 )
2018
33
The involvement of neuroinflammation and necroptosis in the hippocampus during vascular dementia. ( 29759140 )
2018
34
Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. ( 29254092 )
2018
35
Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. ( 29438037 )
2018
36
Plasma tau is increased in frontotemporal dementia. ( 29440230 )
2018
37
Positive age beliefs protect against dementia even among elders with high-risk gene. ( 29414991 )
2018
38
Combined Socio-Behavioral Evaluation Improves the Differential Diagnosis Between the Behavioral Variant of Frontotemporal Dementia and Alzheimer's Disease: In Search of Neuropsychological Markers. ( 29254091 )
2018
39
When Post-Traumatic Stress Disorder and Charles Bonnet Syndrome Become Lewy Body Dementia. ( 29778582 )
2018
40
Why do herpes simplex encephalitis and semantic dementia show a different pattern of semantic impairment in spite of their main common involvement within the anterior temporal lobes? ( 29573378 )
2018
41
Reply: Cerebrospinal Fluid, Hyposmia and Dementia in Alzheimer Disease: Insights from Dynamic PET and a Hypothesis. ( 29439014 )
2018
42
Regional structural hypo- and hyperconnectivity of frontal-striatal and frontal-thalamic pathways in behavioral variant frontotemporal dementia. ( 29923666 )
2018
43
Distinct Interplay Between Atrophy and Hypometabolism in Alzheimer's Versus Semantic Dementia. ( 29668866 )
2018
44
Caregiver Reactions to Dementia Symptoms: Effects on Coping Repertoire and Mental Health. ( 29451843 )
2018
45
Hypotensive Drugs and Syncope Due to Orthostatic Hypotension in Older Adults with Dementia (Syncope and Dementia Study). ( 29897099 )
2018
46
Autoimmunity and Frontotemporal Dementia. ( 29357796 )
2018
47
Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study. ( 29979473 )
2018
48
Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. ( 29942091 )
2018
49
Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis. ( 29378861 )
2018
50
Distinct Patterns of Rich Club Organization in Alzheimer's Disease and Subcortical Vascular Dementia: A White Matter Network Study. ( 29710719 )
2018